Cargando…

Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice

BACKGROUND: Transforming growth factor beta (TGF-β)-Smad2/3 is the major signaling pathway of fibrosis, which is characterized by the excessive production and accumulation of extracellular matrix (ECM) components, including collagen. Although the ECM is an essential component of skeletal muscle, fib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kakutani, Naoya, Takada, Shingo, Nambu, Hideo, Matsumoto, Junichi, Furihata, Takaaki, Yokota, Takashi, Fukushima, Arata, Kinugawa, Shintaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183133/ https://www.ncbi.nlm.nih.gov/pubmed/32334642 http://dx.doi.org/10.1186/s13395-020-00230-9

Ejemplares similares

Protein acetylation in skeletal muscle mitochondria is involved in impaired fatty acid oxidation and exercise intolerance in heart failure
por: Tsuda, Masaya, et al.
Publicado: (2018)

Deletion of NAD(P)H Oxidase 2 Prevents Angiotensin II-Induced Skeletal Muscle Atrophy
por: Kadoguchi, Tomoyasu, et al.
Publicado: (2018)

Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice
por: Furihata, Takaaki, et al.
Publicado: (2021)

Mitochondrial respiration of complex II is not lower than that of complex I in mouse skeletal muscle
por: Maekawa, Satoshi, et al.
Publicado: (2019)

Linoleic acid improves assembly of the CII subunit and CIII2/CIV complex of the mitochondrial oxidative phosphorylation system in heart failure
por: Maekawa, Satoshi, et al.
Publicado: (2019)

Clinical Impact and Associated Factors of Delayed Ambulation in Patients With Acute Heart Failure
por: Ishikawa, Koji, et al.
Publicado: (2019)

Succinyl-CoA-based energy metabolism dysfunction in chronic heart failure
por: Takada, Shingo, et al.
Publicado: (2022)

Sesamin prevents decline in exercise capacity and impairment of skeletal muscle mitochondrial function in mice with high‐fat diet‐induced diabetes
por: Takada, Shingo, et al.
Publicado: (2015)

Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients
por: Shirakawa, Ryosuke, et al.
Publicado: (2019)

Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction
por: Abe, Takahiro, et al.
Publicado: (2020)

The experimental model of transition from compensated cardiac hypertrophy to failure created by transverse aortic constriction in mice
por: Furihata, Takaaki, et al.
Publicado: (2016)

Cardiac-specific loss of mitoNEET expression is linked with age-related heart failure
por: Furihata, Takaaki, et al.
Publicado: (2021)

Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in heart failure patients
por: Yokota, Takashi, et al.
Publicado: (2021)

The AppCare-HF randomized clinical trial: a feasibility study of a novel self-care support mobile app for individuals with chronic heart failure
por: Yokota, Takashi, et al.
Publicado: (2023)

Impact of Inadequate Calorie Intake on Mortality and Hospitalization in Stable Patients with Chronic Heart Failure
por: Obata, Yoshikuni, et al.
Publicado: (2021)

Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
por: Yokota, Takashi, et al.
Publicado: (2017)

Enhanced mitochondrial oxidative metabolism in peripheral blood mononuclear cells is associated with fatty liver in obese young adults
por: Shirakawa, Ryosuke, et al.
Publicado: (2023)

Progressive Mobilization Program for Patients With Acute Heart Failure Reduces Hospital Stay and Improves Clinical Outcome
por: Kakutani, Naoya, et al.
Publicado: (2019)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Abnormalities of Skeletal Muscle, Adipocyte Tissue, and Lipid Metabolism in Heart Failure: Practical Therapeutic Targets
por: Takada, Shingo, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Impaired mitochondrial oxidative phosphorylation capacity in epicardial adipose tissue is associated with decreased concentration of adiponectin and severity of coronary atherosclerosis
por: Nakajima, Takayuki, et al.
Publicado: (2019)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
por: Dézsi, Csaba András, et al.
Publicado: (2016)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Increase in prescription rate of angiotensin-converting enzyme inhibitors or angiotensin receptor blocker for hospitalized patients with acute myocardial infarction and left ventricular systolic dysfunction
por: Makdisse, MRP, et al.
Publicado: (2007)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction
por: Chen, Chih-Wei, et al.
Publicado: (2023)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Cross-disease communication between cancer and heart failure provides a rational approach to prevention and treatment of both diseases
por: Takada, Shingo, et al.
Publicado: (2022)

A Randomized Controlled Trial of Angiotensin-Converting Enzyme Inhibition for Skeletal Muscle Dysfunction in COPD
por: Shrikrishna, Dinesh, et al.
Publicado: (2014)

The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
por: Ishida, Junichi, et al.
Publicado: (2015)

Angiotensin-Converting Enzyme 2: The First Decade
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-I-converting enzyme and its relatives
por: Riordan, James F
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_gt4qu7s60n82465m8v969dob2k